All In Biotech

Drug Trial Radar · NCT07741630

Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Aug 15, 2026

Primary completion

Jun 30, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Peking University Third HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

his is an open-label, single-center, single-arm, prospective Phase II trial evaluating the efficacy and safety of Mirvetuximab Soravtansine (MIRV) combined with Suvemcitug (SV) in patients with folate receptor alpha (FRα)-positive, platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. A total of 20 eligible patients will receive MIRV (6 mg/kg AIBW IV Q3W) and Suvemcitug (1.5 mg/kg IV Q2W) until disease progression or intolerable toxicity. The primary endpoint is investigator-assessed Progression-Free Survival (PFS) per RECIST v1.1.

Conditions

  • PROC

Interventions

  • Mirvetuximab soravtansineDrug

    6 mg/kg adjusted ideal body weight (AIBW), administered intravenously (IV) once every 3 weeks (Q3W).

  • SuvemcitugDrug

    1.5 mg/kg, administered intravenously (IV) once every 2 weeks (Q2W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 20 months (assessed every 6-8 weeks during treatment).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.